ClinicalTrials.govpublic full text
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
hepatocellular carcinoma, locoregional hcc, durvalumab, tremelimumab, lenvatinib, tace, liver cancer, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 868361
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.